Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection
-
Published:2023-05-26
Issue:1
Volume:14
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Perez-Saez Javier, Zaballa María-EugeniaORCID, Lamour JulienORCID, Yerly SabineORCID, Dubos Richard, Courvoisier Delphine S., Villers JenniferORCID, Balavoine Jean-François, Pittet Didier, Kherad Omar, Vuilleumier Nicolas, Kaiser Laurent, Guessous IdrisORCID, Stringhini SilviaORCID, Azman Andrew S.ORCID, Arm-Vernez Isabelle, Bachmann Delphine, Bal Antoine, Barbe Rémy P., Baysson Hélène, Berthelot Julie, Bryand-Rumley Gaëlle, Chappuis François, Collombet Prune, Coudurier-Boeuf Sophie, de Mestral Carlos, D’ippolito Paola, Dumont Roxane, El Merjani Nacira, Flahault Antoine, Francioli Natalie, Graindorge Clément, Harnal Séverine, Hurst Samia, Lescuyer Pierre, L’Huillier Arnaud G., Loizeau Andrea Jutta, Lorthe Elsa, Martinez Chantal, Metral-Boffod Ludovic, Nehme Mayssam, Noël Natacha, Pennacchio Francesco, Posfay-Barbe Klara M., Poulain Géraldine, Pugin Caroline, Pullen Nick, Richard Viviane, Rochat Déborah, Samir Khadija, Ramirez Hugo Santa, Satin Etienne, Schaller Philippe, Schrempft Stephanie, Semaani Claire, Testini Stéphanie, Urrutia-Rivas Déborah, Verolet Charlotte, Vetter Pauline, Violot Guillemette, Wisniak Ania,
Abstract
AbstractBinding antibody levels against SARS-CoV-2 have shown to be correlates of protection against infection with pre-Omicron lineages. This has been challenged by the emergence of immune-evasive variants, notably the Omicron sublineages, in an evolving immune landscape with high levels of cumulative incidence and vaccination coverage. This in turn limits the use of widely available commercial high-throughput methods to quantify binding antibodies as a tool to monitor protection at the population-level. Here we show that anti-Spike RBD antibody levels, as quantified by the immunoassay used in this study, are an indirect correlate of protection against Omicron BA.1/BA.2 for individuals previously infected by SARS-CoV-2. Leveraging repeated serological measurements between April 2020 and December 2021 on 1083 participants of a population-based cohort in Geneva, Switzerland, and using antibody kinetic modeling, we found up to a three-fold reduction in the hazard of having a documented positive SARS-CoV-2 infection during the Omicron BA.1/BA.2 wave for anti-S antibody levels above 800 IU/mL (HR 0.30, 95% CI 0.22-0.41). However, we did not detect a reduction in hazard among uninfected participants. These results provide reassuring insights into the continued interpretation of SARS-CoV-2 binding antibody measurements as an independent marker of protection at both the individual and population levels.
Funder
Private Foundation of the Geneva University Hospitals General Directorate of Health of the canton of Geneva
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|